Search clinical trials for: Autologous Tumor Infiltrating Lymphocytes

Total 37034 results

Grit Biotechnology

Not yet recruiting

Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent or Metastatic Cervical Cancer

Adult

China
M.D. Anderson Cancer Center
KSQ Therapeutics, Inc.

Recruiting

A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors

Melanoma | Head and Neck Neoplasms | Lung Neoplasms | Advanced Solid Tumor

United States
Grit Biotechnology

Recruiting

Clinical Study of GT201 in the Treatment of Advanced Gynecological Tumors (Advanced Cervical Cancer)

Adult | Gynecological Tumors

China
University of Kansas Medical Center
National Cancer Institute (NCI); Iovance Biotherapeutics, Inc.

Recruiting

Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma

Metastatic Melanoma | Unresectable Melanoma | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Clinical Stage IV Cutaneous Melanoma AJCC v8

United States
Shanghai Juncell Therapeutics

Recruiting

A Phase Ⅰb Study on Autologous GC101 TIL Injection for the Treatment of Advanced Melanoma (MIZAR-002) (MIZAR-002)

Melanoma | Efficacy | Adverse Drug Event | Safety | Tumor Infiltrating Lymphocytes

China
Zhiyong Huang
Wuhan Elongevity Technology Co., Ltd.

Recruiting

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Advanced Liver Cancer

Liver Cancer

China
Vastra Gotaland Region

Not yet recruiting

Locoregional Administration of TIL and Lymphodepletion in Patients With Melanoma and Liver Metastases (HAITILS-PHP)

Metastatic Cutaneous Melanoma | Uveal Melanoma
Shanghai General Hospital, Shanghai Jiao Tong University...
RenJi Hospital

Not yet recruiting

Safety and Efficacy of an Autologous Tumor Infiltrating Lymphocyte (TIL) Therapy in Patients With Advanced Solid Tumors

Solid Tumor

China
Iovance Biotherapeutics, Inc.

Recruiting

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

Melanoma | Metastatic Melanoma | Unresectable Melanoma

United States, Spain, Australia, France, Netherlands, Italy, Canada, Sweden
Memorial Sloan Kettering Cancer Center
Iovance Biotherapeutics, Inc.

Recruiting

Pilot Trial of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Patients With Metastatic Uveal Melanoma

Melanoma | Metastatic Melanoma | Metastatic Uveal Melanoma | Uveal Melanoma

United States
Turnstone Biologics, Corp.

Recruiting

A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors (STARLING)

Breast Cancer | Colorectal Cancer | Non-Small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Uveal Melanoma | Cutaneous Melanoma

United States, Canada
Fudan University
Cellular Biomedicine Group Ltd.

Recruiting

Study of C-TIL052A Cell Therapy in Advanced Cervical Cancer (TIL)

Cervical Cancer

China
Shanghai Juncell Therapeutics

Recruiting

A Phase I Study on Autologous Tumor Infiltrating Lymphocytes Injection (GC101 TIL) for the Treatment of Advanced Malignant Solid Tumors (MIZAR-001)

Advanced Solid Tumor | Efficacy | Immunotherapy | Adverse Drug Event | Safety | Tumor Infiltrating Lymphocytes

China
Suzhou BlueHorse Therapeutics Co., Ltd.

Recruiting

A Clinical Study of LM103 Injection in the Treatment of Advanced Solid Tumors

Melanoma | Non Small Cell Lung Cancer | Cervical Carcinoma

China
Iovance Biotherapeutics, Inc.

Recruiting

A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer

Metastatic Melanoma | Unresectable Melanoma | Stage IV Non-small Cell Lung Cancer | Stage III Non-small Cell Lung Cancer

United States
Hebei Senlang Biotechnology Inc., Ltd.

Recruiting

The Safety Study of Autologous TILs Therapy for Patients With Glioblastoma Multiforme.

Glioblastoma Multiforme, Adult

China
Women's Hospital School Of Medicine Zhejiang University
Sun Yat-sen University; Tongji Hospital; Qilu Hospital of Shandong University

Not yet recruiting

Efficacy and Safety of TILs in Treatment of Patients With Advanced or Metastatic Refractory Gynecological Cancer

Tumor Infiltrating Lymphocytes
Vastra Gotaland Region
Miltenyi Biomedicine GmbH

Recruiting

Hepatic Arterial Infusion of Autologous Tumor Infiltrating Lymphocytes in Patients With Melanoma and Liver Metastases (HAITILS)

Metastatic Cutaneous Melanoma | Metastatic Uveal Melanoma

Sweden
Iovance Biotherapeutics, Inc.

Recruiting

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

Metastatic Non Small Cell Lung Cancer

United States, Canada, Germany, Netherlands, Switzerland
Sheba Medical Center

Recruiting

A Phase 2, Single-Center, Open Label Study of Autologous, Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Urothelial Carcinoma Patients

Metastatic Urothelial Carcinoma

Israel
Gregory Daniels
Immunotherapy Foundation

Recruiting

Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors

Metastatic Melanoma | Metastatic Head and Neck Cancer | Locally Advanced Refractory/Recurrent Melanoma | Locally Advanced Refractory/Recurrent Head and Neck Cancer

United States
Iovance Biotherapeutics, Inc.

Recruiting

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

Squamous Cell Carcinoma of the Head and Neck | Metastatic Melanoma | Non-small Cell Lung Cancer

United States, Spain, Canada, France, Germany, Greece, Switzerland, United Kingdom
Iovance Biotherapeutics, Inc.

Recruiting

Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma

Cervical Carcinoma

United States, Spain, United Kingdom, Germany, France, Italy, Netherlands, Switzerland
Karolinska University Hospital

Recruiting

T Cell Transfer With or Without Dendritic Cell Vaccination in Patients With Melanoma

Melanoma

Sweden
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Active, not recruiting

Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1

Metastatic Melanoma | Advanced Malignant Solid Neoplasm | Unresectable Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8 | Pathologic Stage... and other conditions

United States
James Isaacs, MD

Suspended

Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable Melanoma

Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIID Melanoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Iovance Biotherapeutics, Inc.

Active, not recruiting

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

Malignant Solid Neoplasm | Soft Tissue Sarcoma | Recurrent Ovarian Carcinoma | Triple Negative Breast Cancer | Recurrent Osteosarcoma | Refractory Osteosarcoma | Bone Sarcoma | Giant Cell Tumor of Bone | Ovarian Carcinosarcoma | Platinum-Resistant Ovarian Carcinoma | Dedifferentiated Chondrosarcoma | Malignancy... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma

Metastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Stage IIIC Cutaneous Melanoma AJCC v7 | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7

United States
Instil Bio

Terminated

ITIL-168 in Advanced Melanoma (DELTA-1)

Advanced Cutaneous Melanoma

United States, Canada, United Kingdom
University Health Network, Toronto

Active, not recruiting

"Re-Stimulated" TILs And IL-2 Therapy for Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Fallopian Tube Cancer | Primary Peritoneal Cancer | High Grade Serous Ovarian Cancer | Recurrent | Platinum-resistant

Canada
Richard Wu
Iovance Biotherapeutics, Inc.

Active, not recruiting

Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients

Locally Advanced Melanoma | Stage IV Melanoma | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8

United States
Instil Bio

Active, not recruiting

ITIL-306 in Advanced Solid Tumors

Renal Cell Carcinoma | Epithelial Ovarian Cancer | Non-small Cell Lung Cancer

United States
Yale University
Iovance Biotherapeutics, Inc.

Completed

Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastatic Triple Negative Breast Cancer

Metastatic Triple Negative Breast Cancer

United States
M.D. Anderson Cancer Center
Bristol-Myers Squibb; National Cancer Institute (NCI); Iovance Biotherapeutics

Active, not recruiting

Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma

Malignant Solid Neoplasm | Metastatic Colorectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Platinum-Resistant Ovarian Carcinoma | Metastatic Pancreatic Ductal Adenocarcinoma | Metastatic Ovarian Carcinoma and other conditions

United States
Iovance Biotherapeutics, Inc.

Completed

Study of LN-145/LN-145-S1 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & Neck

Squamous Cell Carcinoma of the Head and Neck

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma

Metastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7

United States
Iovance Biotherapeutics, Inc.

Active, not recruiting

Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma (LN-144)

Metastatic Melanoma

United States, Spain, Germany, United Kingdom, France, Hungary, Italy, Switzerland
University Health Network, Toronto

Completed

TILs & Low-Dose IL-2 Therapy Following Cyclophosphamide and Fludarabine in Pleural Mesothelioma Patients

Pleural Mesothelioma

Canada
Instil Bio

Withdrawn

ITIL-168 in Advanced Solid Tumors (DELTA-2)

Cervical Cancer | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma
Yale University

Terminated

A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes

Metastatic Melanoma

United States
Saint John's Cancer Institute

Terminated

A Study Using Tumor-Reactive Autologous Tumor Infiltrating Lymphocytes (TIL) in Metastatic Melanomas (TIL)

Metastatic Melanoma

United States
Centre Hospitalier Universitaire Vaudois

Terminated

Adoptive Transfer Of Autologous Tumor-Infiltrating Lymphocytes in Solid Tumors

Solid Tumor, Adult

Switzerland
Inge Marie Svane

Unknown

Adoptive Cell Therapy Across Cancer Diagnoses

Cancer

Denmark
Roswell Park Cancer Institute
Iovance Biotherapeutics, Inc.

Withdrawn

Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy

Metastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Unresectable Renal Pelvis Urothelial Carcinoma | Unresectable Ureter Urothelial Carcinoma

United States
University of Maryland, Baltimore
University of Maryland Greenebaum Cancer Center

Completed

Chemotherapy and Peripheral Stem Cell Transplantation Followed By Immunotherapy in Treating Patients With Multiple Myeloma

Infection | Multiple Myeloma and Plasma Cell Neoplasm

United States
Iovance Biotherapeutics, Inc.

Withdrawn

Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) In Combo With Durvalumab in Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Terminated

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma

Metastatic Uveal Melanoma | Metastatic Ocular Melanoma

United States
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Completed

Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
National Cancer Institute (NCI)

Completed

Interleukin-2 Plus Activated White Blood Cells in Treating Patients With Cancer That Has Not Responded to Chemotherapy or Radiation Therapy

Unspecified Adult Solid Tumor, Protocol Specific

United States
Aurora Health Care

Terminated

Laboratory-Treated Autologous Lymphocytes and Aldesleukin After Cyclophosphamide and Fludarabine in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States

Search clinical trials for: Autologous Tumor Infiltrating Lymphocytes

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Nigeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations